ACC/AHA Heart‑Failure Staging and NYHA Functional Classification
ACC/AHA Structural Stages (A–D)
The American College of Cardiology/American Heart Association (ACC/AHA) created a four‑stage classification (Stages A‑D) that emphasizes the unidirectional progression of heart‑failure disease and links specific therapeutic interventions to each stage; patients can move forward but cannot revert to an earlier stage. [1][2]3
Stage A – At risk for heart failure – Defined as individuals who possess risk factors (e.g., hypertension, coronary artery disease, diabetes, metabolic syndrome, obesity, exposure to cardiotoxic drugs or alcohol, family history of cardiomyopathy) but have no structural heart disease, symptoms, or cardiac‑stretch/injury biomarkers. 1
Stage B – Pre‑heart failure (structural disease without symptoms) – Defined as patients with structural cardiac abnormalities that are strongly associated with future heart‑failure development (e.g., left‑ventricular hypertrophy or fibrosis, ventricular dilatation or hypocontractility, asymptomatic valvular disease, prior myocardial infarction, reduced left or right ventricular function, elevated filling pressures) who have never manifested symptoms. [1][4]
Stage C – Symptomatic heart failure – Defined as patients who have current or past heart‑failure symptoms together with underlying structural heart disease; once a patient experiences symptoms, they remain classified as Stage C permanently, regardless of subsequent symptom resolution. [1][4]
Stage D – Advanced heart failure – Defined as patients with advanced structural disease and marked symptoms at rest despite maximal medical therapy, requiring specialized interventions such as mechanical circulatory support, continuous intravenous inotropes, heart transplantation, or hospice care. [1][4]
In Stage D, common clinical scenarios include frequent hospitalizations for decompensation, inability to be safely discharged, awaiting transplantation, or receiving long‑term mechanical support. 1
Recommended therapies for Stage D (mechanical circulatory support, continuous inotropic infusion, heart transplantation, palliative care) are endorsed by the ACC/AHA and supported by the cited literature. 4
NYHA Functional Classification (I–IV)
The New York Heart Association (NYHA) functional classification provides a subjective, dynamic assessment of current symptom severity that complements—but does not replace—the ACC/AHA staging system. [2][4]
NYHA classes are mutable and can improve or worsen with therapy, whereas ACC/AHA stages progress only forward. This distinction is highlighted by evidence that stages advance unidirectionally, while NYHA class can change over time. 4
Short‑term fluctuations in NYHA class are common, making NYHA less reliable for long‑term risk stratification compared with the ACC/AHA staging framework. [2][4]
Clinical Implications of Staging vs. Functional Classification
Because ACC/AHA stages are irreversible, treatment strategies are anchored to the stage at which structural disease is first identified, ensuring early‑stage interventions (e.g., risk‑factor control in Stage A) are applied before irreversible remodeling occurs. [1][4]
NYHA class remains an independent predictor of mortality despite its subjectivity, and clinicians should document baseline NYHA class and reassess it throughout care to capture functional changes. [2][4]
Classification and Treatment of Congestive Heart Failure
Overview of Classification Systems
- The American College of Cardiology/American Heart Association (ACC/AHA) staging system categorizes heart failure based on disease progression, including Stage A: At Risk for HF, Stage B: Pre-HF, Stage C: Symptomatic HF, and Stage D: Advanced HF 5, 6, 7
- The New York Heart Association (NYHA) functional classification assesses symptom severity in patients with Stage C or D heart failure, including Class I, Class II, Class III, and Class IV 8
ACC/AHA Staging System
- Stage A: At Risk for HF is characterized by patients with risk factors but no structural heart disease or symptoms, such as hypertension, coronary artery disease, diabetes, metabolic syndrome, obesity, exposure to cardiotoxic agents, and genetic variants for cardiomyopathy 5, 7
- Stage B: Pre-HF includes structural heart disease without symptoms, such as reduced left or right ventricular function, ventricular hypertrophy or chamber enlargement, wall motion abnormalities, valvular heart disease, and elevated filling pressures or elevated cardiac biomarkers 5, 6, 7
- Stage C: Symptomatic HF is characterized by current or previous symptoms of HF with underlying structural heart disease 5, 7
- Stage D: Advanced HF is marked by symptoms that interfere with daily life with recurrent hospitalizations despite optimized medical therapy 5, 6
NYHA Functional Classification
- Class I: No limitation of physical activity; ordinary activity doesn't cause HF symptoms 8
- Class II: Slight limitation of physical activity; comfortable at rest but ordinary activity results in HF symptoms 8
- Class III: Marked limitation of physical activity; less than ordinary activity causes HF symptoms 8
- Class IV: Unable to perform any physical activity without symptoms; symptoms present at rest 8
Classification by Left Ventricular Ejection Fraction (LVEF)
- Heart failure can be classified based on ejection fraction, including HFrEF (HF with reduced EF), HFmrEF (HF with mildly reduced EF), and HFpEF (HF with preserved EF) 5
Treatment Approaches Based on Classification
- For Stage A: At Risk for HF, control hypertension, diabetes, and dyslipidemia, smoking cessation, alcohol moderation, regular exercise, weight management, and avoid cardiotoxic agents 6
- For Stage B: Pre-HF, all Stage A interventions, ACE inhibitors or ARBs for patients with reduced EF, and beta-blockers for patients with prior MI 6
- For Stage C: Symptomatic HF, all Stage A and B interventions, SGLT2 inhibitors for HFrEF, and treatment of underlying conditions for HFpEF 5, 6
- For Stage D: Advanced HF, consideration for advanced therapies, including mechanical circulatory support, continuous inotropic infusions, heart transplantation, and palliative care 6